Was Mounjaro Approved for Weight Loss?

Last reviewed: July 13, 2026

Last updated: July 13, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) was formally approved by the FDA in May 2022 as a once-weekly injection for managing type 2 diabetes—not weight loss. Yet pivotal trials showed participants lost an average of 15–22% of their body weight, sparking widespread curiosity about using the medication for metabolic support beyond blood sugar control.

Understanding Mounjaro's Original FDA Approval

The FDA's initial authorization of Mounjaro targeted adults with type 2 diabetes who needed improved glycemic control. Eli Lilly's approval pathway focused on demonstrating that tirzepatide could lower hemoglobin A1C levels—a key marker of long-term blood sugar management. This diabetes indication was the first and primary labeled use for the medication.

Approval trials enrolled thousands of patients and compared tirzepatide against existing diabetes treatments and placebo. Researchers measured insulin secretion, appetite suppression, and metabolic markers alongside blood glucose outcomes. The clinical evidence consistently showed that tirzepatide addressed multiple pathways involved in both glucose regulation and energy balance.

Why Tirzepatide Produces Weight Loss Even Though It Wasn't Approved for It

Tirzepatide works by activating two hormone receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both receptors influence appetite centers in the brain, slow stomach emptying, and regulate blood sugar. When participants in diabetes trials took tirzepatide, these dual actions produced weight loss as a natural consequence of reduced caloric intake and improved metabolic signaling.

The weight reduction wasn't a surprise finding—it appeared in every major trial and across all dose levels. Participants on tirzepatide experienced sustained appetite suppression, increased feelings of fullness, and reduced food cravings. This metabolic effect occurs whether the patient has diabetes or not, which is why the medication has become relevant for individuals managing weight without a diabetes diagnosis.

The Difference Between Mounjaro and Zepbound

Recognizing tirzepatide's weight loss potential, Eli Lilly developed Zepbound in 2023—the same active ingredient in a formulation and dosing schedule specifically designed for chronic weight management. Zepbound carries an explicit FDA approval for weight loss in adults with obesity or overweight status plus at least one weight-related health condition. Mounjaro remains labeled only for diabetes.

From a clinical standpoint, both medications contain identical tirzepatide compound. The difference lies in labeling, marketing, and how healthcare providers justify prescribing the medication. Some clinicians still prescribe Mounjaro off-label for weight management in eligible patients, while others prefer Zepbound's dedicated indication.

Accessing Tirzepatide Through PlexusDx

PlexusDx offers compounded tirzepatide injection prepared by licensed 503A compounding pharmacies at a flat monthly rate of $289, regardless of your prescribed dose level. This pricing model means your dose may need to go up as your treatment progresses—but your monthly payment stays the same, eliminating cost surprises and dose-stacking anxiety.

PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorizations. Medications qualify for HSA and FSA account withdrawals, reducing out-of-pocket burden. The Precision Peptide Genetic Test ($99 add-on after your first month) maps 14 metabolic pathways and 49 peptides to help describe the pathway-level variants involved in GLP1R, GIPR, FTO, and MC4R genes.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I use Mounjaro for weight loss if I don't have type 2 diabetes?

Mounjaro's FDA label restricts it to diabetes management, making off-label use for weight loss a conversation between you and your prescriber. Zepbound carries explicit weight loss approval and may be a more appropriate choice if weight management is your primary goal. PlexusDx offers both tirzepatide formulations through licensed compounding pharmacies.

How much weight do people typically lose on tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What is the monthly cost of tirzepatide at PlexusDx?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) on a flat-rate model—meaning dose increases don't trigger price increases. PlexusDx serves all 50 states, accepts HSA/FSA funding, and does not require insurance or membership fees.

Are there safety concerns with using tirzepatide off-label for weight loss?

Tirzepatide has a well-documented safety profile from thousands of patients in clinical trials. Common side effects include nausea, vomiting, and diarrhea, typically mild and temporary. Serious adverse events are rare. Any off-label use must be supervised by a licensed provider who can monitor your response and adjust dosing.

How can the Precision Peptide Genetic Test help me choose between GLP-1 or tirzepatide?

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes plus 46 additional peptide pathways to identify your metabolic profile. This $99 add-on test (after your first treatment month) can reveal whether you're more responsive to single-agent GLP-1 or dual-compound tirzepatide therapy, personalizing your weight loss strategy.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.